OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors

In advanced epidermal growth factor receptor (EGFR) mutant lung cancer, the role of immune checkpoint inhibitors (ICI), following disease progression with tyrosine kinase inhibitors (TKIs), remain uncertain. Although treatment outcomes with ICI monotherapy have been poor, ICIs and chemotherapy combination have been shown to improve survival over chemotherapy alone in this population. We conducted a phase II study aimed to determine the efficacy and tolerability of dual ICI therapy, durvalumab and tremelimumab, with platinum-pemetrexed chemotherapy, in metastatic EGFR mutant lung cancer following progression with EGFR TKIs.